A new pharmaceutio form primaquine-liposome (PQ-Lip) was prepared, and the toxieity and therapeutic eftiioaey of PQ-Lip in mice were determined. Bos alts showed that the LD50 of i.v. PQ-Lip in mice was about 2-3 times less than free PQ. PQ-Lip concentration in blood was higher than free PQ in blood (at the begining of 2h). After i.v. administration in mice, PQ-Lip showed a higher concentration in the spleen and liver, and a lesser uptake by the lung ang heart.